Impact of pattern of recurrence on post-relapse survival according to surgical timing in patients with advanced ovarian cancer.


Journal

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626

Informations de publication

Date de publication:
03 01 2023
Historique:
pubmed: 30 11 2022
medline: 10 1 2023
entrez: 29 11 2022
Statut: epublish

Résumé

Our study aimed to evaluate the association between timing of cytoreductive surgery and pattern of presentation of the first recurrence in patients with advanced ovarian cancer. We also aimed to assess the impact of the pattern of recurrence on post-relapse overall survival according to surgical timing. This retrospective multicenter study evaluated patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIIC-IV ovarian cancer. Patients had undergone either primary debulking surgery, early interval debulking surgery after 3-4 cycles of neoadjuvant chemotherapy, or delayed debulking surgery after 6 cycles, with minimal or no residual disease, between January 2008 and December 2015. Survival analyses were conducted using the Log-rank test and the Cox model. Cumulative incidences of the different patterns of recurrence were estimated using a competing risks methodology. A total of 549 patients were included: 175 (31.9%) patients had primary, 224 (40.8%) early interval, and 150 (27.3%) delayed debulking surgery. The cumulative incidence of peritoneal recurrences at 2 years was higher with increasing neoadjuvant cycles (24.4%, 30.9% and 39.2%; p=0.019). For pleural or pulmonary recurrences, it was higher after early interval surgery (9.9%, 13.0% and 4.1%; p=0.022). Median post-relapse overall survival was 33.5 months (95% confidence interval (CI) (24.3 to 44.2)), 26.8 months (95% CI (22.8 to 32.6)), and 24.5 months (95% CI (18.6 to 29.4)) for primary, early interval, and delayed debulking surgery groups, respectively (p=0.025). The pattern of recurrence in a lymph node (hazard ratio (HR) 0.42, 95% CI (0.27 to 0.64)), delayed surgery (HR 1.53, 95% CI (1.11 to 2.13)) and time to first recurrence (HR 0.95, 95% CI (0.93 to 0.96)) were associated with post-relapse overall survival. For primary and early interval surgery, lymph node recurrences were associated with significantly longer post-relapse overall survival. The pattern of first recurrence was associated with timing of surgery, with peritoneal recurrences being more frequent with the increasing number of cycles of neoadjuvant chemotherapy. Lymph node recurrences were associated with better prognosis, having higher post-relapse overall survival. This improved prognosis of lymphatic recurrences was not observed in patients who underwent delayed surgery.

Identifiants

pubmed: 36446410
pii: ijgc-2022-003985
doi: 10.1136/ijgc-2022-003985
doi:

Types de publication

Multicenter Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

50-56

Informations de copyright

© IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Martina Aida Angeles (MA)

Department of Surgical Oncology, Institut Claudius Regaud, Toulouse, Occitanie, France martinangeles22@hotmail.com.

Emanuela Spagnolo (E)

Gynecologic Oncology Unit, La Paz University Hospital, Madrid, Spain.

Bastien Cabarrou (B)

Biostatistics Unit, Institut Claudius Regaud, Toulouse, Occitanie, France.

Assumpció Pérez-Benavente (A)

Gynecologic Oncology Unit, Gynecology Department, Hospital Vall d'Hebron, Barcelona, Catalunya, Spain.

Antonio Gil Moreno (A)

Gynecology, Vall d'Hebron Hospital, SANT CUGAT DEL VALLÉS, Barcelona, Spain.
Universitat Autònoma de Barcelona, Barcelona, Spain.

Frederic Guyon (F)

Institut Bergonié, Bordeaux, Aquitaine, France.

Agnieszka Rychlik (A)

Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Warszawa, Poland.

Federico Migliorelli (F)

Institut Clínic de Ginecologia, Obstetrícia i Neonatologia, BCNatal, Barcelona Center for Maternal-Fetal and Neonatal Medicine (Hospital Clínic and Hospital Sant Joan de Déu), Barcelona, Spain.

Guillaume Bataillon (G)

Department of Anatomopathology, Institut Claudius Regaud, Toulouse, Occitanie, France.

Anne-Sophie Navarro (AS)

Department of Surgical Oncology, Institut Claudius Regaud, Toulouse, Occitanie, France.

Sarah Betrian (S)

Department of Medical Oncology, Institut Claudius Regaud, Toulouse University Cancer 32 Institute (IUCT), Oncopole, Toulouse, France.

Gwenael Ferron (G)

Department of Surgical Oncology, Institut Claudius Regaud, Toulouse, Occitanie, France.

Alicia Hernández (A)

Gynecologic Oncology Unit, La Paz University Hospital, Madrid, Spain.

Alejandra Martinez (A)

Department of Surgical Oncology, Institut Claudius Regaud, Toulouse, Occitanie, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH